Ophthalmology Breaking News

👁 Stay Ahead in Ophthalmology with OBN Join a community of over +53,000 professionals from medical experts to key opinion leaders. 📌 Don't miss out on the latest advancements and technologies. 📌 Get weekly latest updates every Friday straight into your inbox. 📌 Access exclusive articles and interviews. Don't miss out on the opportunity to stay informed and connected, subscribe now and receive free updates every week. https://lnkd.in/dbN2-tdZ #Ophthalmology #Newsletter #Healthcare #MedicalUpdates #OphthalmologyNews #OBN

🔬 Nona Biosciences and Kodiak Sciences Join Forces to Develop Cutting-Edge Ophthalmic Antibodies  In an exciting new partnership, Nona Biosciences and Kodiak Sciences Inc. are working together to develop innovative multi-target antibodies for treating complex ophthalmic diseases. This collaboration leverages Nona’s advanced Harbour Mice platform, known for generating fully human monoclonal and heavy chain-only antibodies (HCAbs) that streamline development and enable next-generation therapies. “This partnership underscores our commitment to advancing next-generation therapies and accelerating innovative treatments for patients,” said Dr. Jingsong Wang, Chairman of Nona Biosciences. 🔗 Learn more about how this collaboration is advancing ophthalmic care here: https://lnkd.in/dzHiA7rp #Collaboration #Innovation #EyeHealth #ScientificResearch #Ophthalmology

🔬 ViaLase, Inc and John A. Moran Eye Center Join Forces to Revolutionize Glaucoma Care  ViaLase has partnered with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation, to advance glaucoma research and treatment. This collaboration leverages Moran’s cutting-edge iPerfusion technology to explore the effects of ViaLase’s femtosecond laser procedure on aqueous humor outflow and intraocular pressure (IOP) dynamics. 📊 Key Highlights: • The ViaLase laser procedure creates precise channels through the trabecular meshwork and Schlemm’s canal to enhance fluid drainage and lower IOP. • Research will focus on channel creation, optimal placement, and their effects on glaucoma management. • Led by a world-class team of experts, including Dr. Ike Ahmed, Dr. Fiona McDonnell, and Dr. Ian Pitha. “This partnership has the potential to redefine interventional glaucoma treatment through precision medicine and innovation,” said Dr. Ahmed. 🔗 Discover how this collaboration is paving the way for the future of glaucoma care here: https://lnkd.in/dKpXMcuf #Glaucoma #Collaboration #Innovation #EyeHealth #ScientificResearch

First edition of OBN's Annual Recap Series is here! The ophthalmology industry witnessed some groundbreaking deals in 2024! From major financial investments to strategic partnerships, these acquisitions are reshaping the landscape of eye care innovation. Swipe through to explore the top 10 acquisitions of the year. 🔗 Want to dive deeper into the financial details and strategic moves behind these transformative acquisitions? Discover the full story behind the deals here: https://lnkd.in/dSUCnygt #Ophthalmology #HealthcareInnovation #EyeCare #MedicalAcquisitions

🔎Empagliflozin Shows Promise in Slowing Diabetic Retinopathy Progression  A recent study by Brigham and Women's Hospital reveals that empagliflozin (Jardiance), a sodium-glucose cotransporter-2 inhibitor (SGLT2i), may reduce the progression of diabetic retinopathy (DR) by 22% in patients with preexisting nonproliferative diabetic retinopathy (NPDR). While more research is needed on long-term effects and patient-specific outcomes, these results position empagliflozin as a potential tool for managing DR progression in patients with preexisting conditions. 🔗 Discover the full details and implications of this study here: https://lnkd.in/dbgEG49E #DiabeticRetinopathy #DiabeticEyeDisease #ClinicalTrial #Innovation #EyeHealth

💡 Innovative Treatment for Post-Cataract Surgery Inflammation  Exciting results from a phase 2 clinical trial show that VVN461, a nonsteroidal dual Janus kinase 1/tyrosine kinase 2 immunomodulator developed by VivaVision Biotech, Inc., effectively reduces inflammation and pain following cataract surgery. 📊 Key Findings: • 60% of patients using VVN461 1% achieved complete inflammation resolution by day 14, compared to just 19.4% in the control group. • Significant reduction in anterior chamber flare and pain, with therapeutic effects seen as early as day 3. • Safety confirmed: Adverse events were similar to the control group, making it a promising alternative to corticosteroids. “VVN461 offers a safer alternative to corticosteroids, addressing a critical need for effective anti-inflammatory therapies,” says Dr. Jason Bacharach. 🔗 Read the full article here: https://lnkd.in/gMV2zi54 #ClinicalTrial #Cataract #Treatment #Innovation #EyeHealth #VisionCare

🔬 Groundbreaking Research on AMD from UC Irvine 👁️ New insights into age-related macular degeneration (AMD) reveal that accumulated DNA damage in the retina plays a critical role in its progression. Researchers at UC Irvine have identified how this damage, a hallmark of aging, disrupts retinal function and accelerates vision loss. 🔎 Key Findings Include: • The retina’s high oxygen demand makes it vulnerable to oxidative stress and DNA damage. • A mouse model with impaired DNA repair showed early signs of visual impairment and retinal changes mirroring human AMD. • Potential strategies include enhancing DNA repair, counteracting oxidative stress, and removing damaged cells. With AMD affecting 200,000 Americans annually, these discoveries could lead to preventative interventions and improved quality of life for millions. 🔗 Learn more about this breakthrough research here: https://lnkd.in/dQb-ZdCh #AMD #VisionLoss #ScientificResearch #EyeHealth #Innovation

🌟 2024: A Year of Breakthroughs in Ophthalmology 👁️ From groundbreaking treatments to cutting-edge technologies, 2024 has been a landmark year for advancements in ophthalmology research. These innovations are pushing the boundaries of science, offering hope and improved outcomes for millions affected by vision challenges. 💡 Top Highlights Include: 🔬 A promising new therapy for corneal endothelial disease. 💊 Novel gene editing methods tackling genetic eye disorders. 👓 Smart contact lenses revolutionizing glaucoma monitoring. 💥 Robotic radiotherapy transforming wet AMD treatment. These breakthroughs showcase the relentless dedication of researchers and scientists in advancing global eye care. 🔗 Discover the full list of top 10 breakthroughs here: https://lnkd.in/dg_DhJ5Q #EyeHealth #Innovation #ScientificResearch #Ophthalmology #Breakthroughs #FutureOfVision

🌍 Advancing Global Eye Health: OneSight Partners with WHO  The OneSight EssilorLuxottica Foundation has joined forces with the World Health Organization (WHO) to advance the transformative SPECS 2030 initiative. This collaboration aims to increase effective refractive error coverage by 40% by 2030, addressing the global vision crisis and improving access to care for underserved communities worldwide. 🗨️ Key Focus Areas: ✔️ Expanding refractive services ✔️ Building eye care professional capacity ✔️ Raising public awareness ✔️ Reducing costs of vision care ✔️ Strengthening research and data efforts This partnership is shaping sustainable solutions to transform lives and ensure a brighter future for millions. 🔗 Learn more about this impactful initiative here: https://lnkd.in/dv9fUh8V #GlobalHealth #EyeHealth #Collaboration #SPECS2030 #VisionForEveryone #Innovation

Welcome to OBN's Ophthalmology Newsletter! This edition focuses on significant breakthroughs and updates in ophthalmology, from promising clinical trials to groundbreaking research on nerve regrowth and neural pathways. Let’s dive into the latest developments shaping the future of eye care. ⬇️ Click below to see what’s happening. #Ophthalmology #EyeCare #Glaucoma #TBI #Uveitis #EyeHealth #ClinicalTrials